Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties
@article{NewmanTancredi2011ComparativePO, title={Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties}, author={Adrian Newman-Tancredi and Mark S. Kleven}, journal={Psychopharmacology}, year={2011}, volume={216}, pages={451-473} }
RationaleThere is increasing interest in antipsychotics intended to manage positive symptoms via D2 receptor blockade and improve negative symptoms and cognitive deficits via 5-HT1A activation. Such a strategy reduces side-effects such as the extrapyramidal syndrome (EPS), weight gain, and autonomic disturbance liability.ObjectiveThis study aims to review pharmacological literature on compounds interacting at both 5-HT1A and D2 receptors (as well as at other receptors), including aripiprazole…
139 Citations
Differential control of dopamine ascending pathways by serotonin2B receptor antagonists: New opportunities for the treatment of schizophrenia
- Psychology, BiologyNeuropharmacology
- 2016
Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions.
- Psychology, MedicineCNS & neurological disorders drug targets
- 2013
The functional roles and mechanisms of 5-HT receptors in the treatment of schizophrenia are reviewed, focusing on the serotonergic modulation of cognitive and extrapyramidal motor functions, and illustrates future therapeutic strategies.
Aripiprazole, A Drug that Displays Partial Agonism and Functional
Selectivity
- Psychology, MedicineCurrent neuropharmacology
- 2017
A combination of factors such as dopamine system stabilization via partial agonism, functional selectivity at D2 receptors, and serotonin-dopamine system interaction may contribute to the ability of aripiprazole to successfully manage schizophrenia symptoms.
Classics in Chemical Neuroscience: Aripiprazole.
- PsychologyACS chemical neuroscience
- 2017
Aripiprazole's polypharmacology, characterized by its unique agonist activity at dopamine D2 and D3 and serotonin 5-HT1A receptors, translates to successful reduction of positive, negative, and cognitive symptoms of schizophrenia, while also mitigating risk of weight gain and movement side effects.
Dopamine D2 and serotonin 5‐HT1A receptor interaction in the context of the effects of antipsychotics – in vitro studies
- Biology, PsychologyJournal of neurochemistry
- 2016
The results indicate that the D2‐5‐HT1A complex possesses biochemical, pharmacological, and functional properties distinct from those of mono‐ and homomers.
Involvement of presynaptic 5-HT1A receptors in the low propensity of brexpiprazole to induce extrapyramidal side effects in rats
- Biology, PsychologyPharmacology Biochemistry and Behavior
- 2017
Evaluation of dopamine D2/D3 and serotonin 5-HT2A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography
- Psychology, MedicinePsychopharmacology
- 2012
Compared with olanzapine, lurasidone preferentially binds to D2/D3 receptors rather than 5-HT2A receptors in common marmosets, suggesting that the contribution of in vivo 5- HT2A receptor blocking activity to the pharmacological profile of lurasIDone might differ from olanZapine in terms of the low risk of extrapyramidal syndrome and efficacy against negative symptoms.
Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research
- Psychology, BiologyCNS Drugs
- 2013
In agreement with pharmacological studies, presynaptic and postsynaptic 5- HT1A-R activation appears necessary for anxiolytic and antidepressant effects, respectively, yet, neurodevelopmental roles for 5-HT 1A-Rs are also involved.
Brexpiprazole II: Antipsychotic-Like and Procognitive Effects of a Novel Serotonin-Dopamine Activity Modulator
- Psychology, BiologyThe Journal of Pharmacology and Experimental Therapeutics
- 2014
The results indicate that brexpiprazole has antipsychotic-like activity and robust efficacy in relevant models of cognitive impairment associated with schizophrenia, and the pharmacologic profile of brexpIPrazole is proposed to be based on its balanced effects on 5-HT1A, D2, and 5- HT2A receptors, with possible modulating activity through additional monoamine receptors.
Repeated Clozapine Increases the Level of Serotonin 5-HT1AR Heterodimerization with 5-HT2A or Dopamine D2 Receptors in the Mouse Cortex
- Biology, PsychologyFront. Mol. Neurosci.
- 2018
Ketamine was used to induce cognitive deficits in mice and confirmed the co-localization of D2/5- HT1A and 5-HT1A/5 -HT2A receptors in the mouse cortex, and affected the formation of GPCR heterodimers, which are new targets for the treatment of schizophrenia.
References
SHOWING 1-10 OF 251 REFERENCES
The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
- Psychology, BiologyCurrent opinion in investigational drugs
- 2010
The balance of 5-HT1A/D2 receptor properties should be considered when selecting compounds as antipsychotic development candidates and such differences are likely to translate into distinct therapeutic profiles.
Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
- Psychology, MedicineEuropean journal of pharmacology
- 2009
Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
- Psychology, BiologyThe Journal of pharmacology and experimental therapeutics
- 2000
Clinical studies of antipsychotics interacting with 5-HT(1A) receptors are required to establish their genuine pertinence to the-hopefully improved-treatment of schizophrenia.
Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats
- Psychology, BiologyPsychopharmacology
- 2007
It is demonstrated that some putative antipsychotics with pronounced 5-HT1A agonists activity, coupled with partial agonist activity at DA D2 receptors, markedly diminish PPI of the startle reflex in rats, raising the issue of the influence of such compounds on sensorimotor gating in humans.
Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics
- Psychology, BiologyBehavioural pharmacology
- 2007
Data support the contention that 5-HT1A receptor activation greatly reduces or prevents the cataleptogenic potential of novel antipsychotics, and emphasize that interactions at 5- HT1A and D2 receptors, and the nature of effects at the latter has a profound influence on pharmacological activities, and is likely to affect therapeutic profiles.
Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
- Psychology, BiologyEuropean journal of pharmacology
- 2006
The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment
- Psychology, BiologyPsychopharmacology
- 2010
Multiple 5-HT receptors contribute to effective treatments to reverse adverse effects of NMDA-RA which model psychosis and cognitive impairment, suggesting the importance of the constitutive activity of 5- HT2C receptors in NOR.
SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats
- Psychology, BiologyNeuropharmacology
- 2004
Actions of Novel Antipsychotic Agents on Apomorphine-Induced PPI Disruption: Influence of Combined Serotonin 5-HT1A Receptor Activation and Dopamine D2 Receptor Blockade
- Psychology, BiologyNeuropsychopharmacology
- 2006
Antipsychotics possessing agonist efficacy at 5-HT1A receptors exhibit diverse profiles against apomorphine-induced PPI deficits, depending on the balance between D2 and 5- HT1A activities, suggesting that they may display distinct activity on some aspects of gating deficits in schizophrenic patients.
Serotonin receptors : their key role in drugs to treat schizophrenia
- Psychology, BiologyProgress in Neuro-Psychopharmacology and Biological Psychiatry
- 2003